Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm»

Until clinical trials of efficacy and safety are obtained, routine use of barycytinib in patients with COVID-19 cannot be recommended

Rationality of routine clinical use of olokizumab in COVID-19

Routine clinical use of olokizumab in COVID-19 is not recommended. The use of olokizumab is possible in clinical trials

Is it possible to use riamilovir to prevent infection and treat COVID-19?

Routine clinical use of riamilovir in COVID-19 is not recommended. The use of riamilovir is possible in clinical trials

Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis

Impaired kidney function may influence pharmacokinetics of most of the drugs, including the ones used in COVID-19. In this publication, the most important pharmacokinetic parameters and dose adjustment approaches are provided, based on The Renal Drug Handbook и Sanford Guide. In the majority of cases, mild kidney function reduction does not necessitate dose adjustment. Each case should be considered individually, measuring benefits against risks

Current and future use of remdesivir in patients with COVID-19

There are prerequisites for the use of remdesivir against SARS-CoV-2 in stationary conditions. Remdesivir is not registered in the Russian Federation. The preliminary results of randomized clinical trials on the efficacy of remission are contradictory

Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy

There are no data on the clinical efficacy of the preparation containing sodium aminodihydrophthalazindione in «cytokine storm», including in patients with COVID-19. Protocols of planned or ongoing clinical trials of a preparation containing sodium aminodihydrophthalazindione at COVID-19 have not been found. The use of sodium aminodihydrophthalazindione in the treatment of COVID-19 is possible only in clinical trials

What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?

Some guidelines describe combined use of hydroxychloroquine and lopinavir/ritonavir as one of the treatment alternatives for severe COVID-19, yet this treatment is not preferable. It requires careful consideration of possible interactions with other drugs, monitoring of cardiotoxicity (including QT-interval measurement), and hepatotoxicity (measurement of ASAT/ ALAT)

Current and future use of dipyridamole in patients with COVID-19

Current use of dipyridamole in COVID-19 is mainly based on its antithrombotic activity, since there is no robust clinical effectiveness data. The decision to use dipyridamole in COVID-19 should be individualized, considering the experimental nature of this treatment

Current and future use of umifenovir in patients with COVID-19

At the time of print, the evidence for using umifenovir in COVID-19 is mainly theoretical. The published clinical trials have contradicting results. The decision to use umifenovir in COVID-19 should be individualized, considering the “experimental” nature of this treatment